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Introduction
Macrophage activation syndrome (MAS) is a life-threa-
tening complication of chronic rheumatic disease in
childhood.
Objectives
We aim to eveluate MAS findings and outcomes that
differ according to disease in childhood.
Methods
We obtain 11 rheumatic patients followed in two differ-
ent pediatric rheumatology units (Erciyes University and
Ege University) who presented with MAS. We report
their clinical and laboratory findings, therapies and
outcomes.
Results
The primary diagnoses of the patients included in the
study, respectively; systemic juvenil idiopathic arthritis
(n=5), Systemic Lupus Erythematosus (n=2), juvenile der-
matomyositis (n=2), a neonatale onset multisystem
inflammatory disease (NOMID) and a microscopic poly-
artritis nodosa. The mean age of the patients was
9.9 years old (1-14), and male to female ratio was 3:8.
The mean duration of underlying disease was 6 months
(1-24 months) at the diagnosis of MAS. We found MAS
due to infection in four patients ,while used medicine in
a patient. MAS were developed spontaneously in 6
patients. The clinical manifestations of MAS included
fever 7 (63.6%),mucosal bleading 6 (54.5%), neurologic
involvement 4 (36.4%) and hepatomegaly 6 (54.5%).
We found thrombocytopenia in 9 (81.8%), leucopenia
in 5 (45.5 %), increased AST in 7 (63.6%),
hypofibrinogenemia in 6 (54.5%), increased ferritin in
11 (100%), decreased ESH in 4 (36.4%) and increased
triglyceride in 10 (90.9%) patients. We investigated bone
marrow in all patients, and hemophagocytosis were
determinated in 8 (72.7%). The medications were pulse
methylprednisolone 6 (54.5%), intravenous immunoglo-
bulin 8 (72.7%), plasma exchange 5 (45.5%), cyclosporine
6 (54.5%), dexamethasone 1 (9.1%), etoposide 1 (9.1%).
The prognosis of patients were recovery 8 (72.7%), and
exitus 3 (27.3%).
Conclusion
In conclusion, MAS can be developed in various pedia-
tric rheumatologic disease and fatal. Prompt recognition
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